Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 20
- Registration Number
- NCT02659540
- Locations
- 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
- First Posted Date
- 2016-01-01
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT02644967
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Icahn School Of Medicine at Mount Sinai, New York, New York, United States
Sequential Combo Immuno and Target Therapy (SECOMBIT) Study
- Conditions
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Fondazione Melanoma Onlus
- Target Recruit Count
- 251
- Registration Number
- NCT02631447
- Locations
- 🇨🇭
University Hospital Zurich, Zurich, Switzerland
🇮🇹IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
🇪🇸Clinica Universidad de Navarra, Pamplona, Spain
Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Grupo Español Multidisciplinar de Melanoma
- Target Recruit Count
- 52
- Registration Number
- NCT02626962
- Locations
- 🇪🇸
H. C. U. de Valladolid, Valladolid, Spain
🇪🇸H. U. Virgen de la Victoria, Malaga, Spain
🇪🇸Hospital La Paz, Madrid, Spain
A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Italian Network for Tumor Biotherapy Foundation
- Target Recruit Count
- 19
- Registration Number
- NCT02608437
- Locations
- 🇮🇹
Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena, Italy
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 533
- Registration Number
- NCT02599402
- Locations
- 🇬🇧
Mount Vernon Hospital, Northwood, United Kingdom
🇬🇧Local Institution, Truro, United Kingdom
A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 182
- Registration Number
- NCT02545075
- Locations
- 🇨🇳
Local Institution, Shanghai, China
A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors
- First Posted Date
- 2015-08-06
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT02516527
- Locations
- 🇨🇳
Local Institution, Guangzhou, Guangdong, China
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1301
- Registration Number
- NCT02506153
- Locations
- 🇺🇸
Illinois CancerCare-Macomb, Macomb, Illinois, United States
🇺🇸Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States
🇺🇸McFarland Clinic - Ames, Ames, Iowa, United States
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Lawrence Fong
- Target Recruit Count
- 15
- Registration Number
- NCT02506114
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.